Kura Oncology, Inc.
Precision-oncology company commercializing ziftomenib in NPM1-mutated AML and expanding it into frontline combination regimens.
Hematologic malignancies / precision oncology · Targeted small molecules · Commercial + Phase 3
Precision-oncology company commercializing ziftomenib in NPM1-mutated AML and expanding it into frontline combination regimens.
Hematologic malignancies / precision oncology · Targeted small molecules · Commercial + Phase 3